BackPoseida Therapeutics Overview

Poseida Therapeutics Research & Development

Research & Development expenses for PSTX.

Quarterly R&D Expenses

$41.91M
↑ 11.82% YoY

As of Sep 30, 2024

Annual R&D Expenses (TTM)

$169.70M
↑ 14.18% YoY

Trailing 12 months ending Sep 30, 2024

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin